IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0463237
(2006-08-08)
|
등록번호 |
US-8097269
(2012-01-17)
|
발명자
/ 주소 |
- Pantelidis, Dimitrios
- Bravman, John C.
- Rothbard, Jonathan
- Klein, Richard L.
|
출원인 / 주소 |
- Celonova Biosciences, Inc.
|
대리인 / 주소 |
Rissman Hendricks & Oliverio LLP
|
인용정보 |
피인용 횟수 :
0 인용 특허 :
18 |
초록
Implantable medical devices employing a sol-gel composition coatings that functions as a bioactive material reservoir, and the use of sol-gel composition coatings for improved adhesion of organic and inorganic substrates are disclosed.
대표청구항
▼
1. A medical device comprising a structural element and a bioactive material reservoir, wherein said bioactive material reservoir comprises a coating applied to the surface of said structural element wherein said coating comprises one or more layers and wherein at least one of said layers comprises
1. A medical device comprising a structural element and a bioactive material reservoir, wherein said bioactive material reservoir comprises a coating applied to the surface of said structural element wherein said coating comprises one or more layers and wherein at least one of said layers comprises a matrix composition having an inorganic oxide formed using a sol-gel process wherein the inorganic oxide is compounded with an agent that modifies a characteristic of said inorganic oxide selected from the group consisting of hydrophobicity, charge, biocompatibility, mechanical properties, bioactive material affinity, storage capacity, and combinations thereof wherein the environment of said sol-gel process was is tailored to the characteristics of a bioactive material to be incorporated into said matrix composition said tailoring affecting the amount of said bioactive material within said matrix composition once formed and/or the rate of release of said bioactive material into the physiological environment once implanted in a patient. 2. The medical device according to claim 1, wherein said inorganic oxide is selected from the group consisting of an oxide of silicon and an oxide of titanium. 3. The medical device according to claim 1, wherein said modifying agent is an organically modified silane. 4. The medical device according to claim 3, wherein said organically modified silane is selected from the group consisting of alkylsilanes; methyltrimethoxysilane; methyltriethoxysilane; dimethyldiethoxysilane;trimethylethoxysilane; vinyltrimethoxysilane; vinyltriethoxysilane; ethyltriethoxysilane;isopropyltriethoxysilane; butyltriethoxysilane; octyltriethoxysilane;dodecyltriethoxysilane; octadecyltriethoxysilane; aryl-functional silanes;phenyltriethoxysilane; aminosilanes; aminopropyltriethoxysilane;aminophenyltrimethoxysilane; aminopropyltrimethoxysilane; acrylate functional silanes;methacrylate-functional silanes; acryloxypropyltrimethoxysilane; carboxylate;phosphonate; ester; sulfonate; isocyanate; epoxy functional silanes; chlorosilanes;chlorotrimethylsilane; chlorotriethylsilane; chlorotrihexylsilane; dichlorodimethylsilane;trichloromethylsilane; N,O-Bis (trimethylsilyl)-acetamide (BSA); N,O-Bis (trimethylsilyl) trifluoroacetamide (BSTFA); hexamethyldisilazane (HMOS);methyltrimethylsilyltrifluoroacetamide (MSTFA); N-methyl-N-(tbutyldimethylsilyl) trifluoroacetamide (MTBSTFA); trimethylchlorosilane (TMCS);trimethylsilyimidazole (TMSI); and combinations thereof. 5. The medical device according to claim 1, wherein said bioactive material is selected from the group consisting of an anti-restenotic agent, an anti-inflammatory agent, an HMG-CoA reductase inhibitor, an antimicrobial agent, an antineoplastic agent, an angiogenic agent, an anti-angiogenic agent, a thrombolytic agent, an antihypertensive agent, an anti-arrhythmic agent, a calcium channel blocker, a cholesterol-lowering agent, a psychoactive agent, an anti-depressive agent, an anti-seizure agent, a contraceptive, an analgesic, a bone growth factor, a bone remodeling factor, a neurotransmitter, a nucleic acid, an opiate antagonist and combinations thereof. 6. The medical device according to claim 1, wherein said bioactive material is selected from the group consisting of paclitaxel, rampamycin, everolimus, tacrolimus, sirolimus, des-aspartate angiotensin I, nitric oxide, apocynin, gammatocopheryl, pleiotrophin, estradiol, aspirin, atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and combinations thereof. 7. The medical device according to claim 1 wherein said medical device is a device selected from the group consisting of a vascular conduit, a stent, a plate, a screw, a spinal cage, a dental implant, a dental filling, a brace, an artificial joint, an embolic device, a ventricular assist device, an artificial heart, a heart valve, a venous filter, a staple, a clip, a suture, a prosthetic mesh, a pacemaker, a pacemaker lead, a defibrillator, a neurostimulator, a neurostimulator lead, an implantable sensor, and an external sensor. 8. A medical device comprising a structural element and a bioactive material-eluting coating, wherein said bioactive material-eluting coating comprises at least one layer applied over the surface of said medical device wherein said at least one layer is formed using a sol-gel process and comprises an organically modified silane. 9. A medical device according to claim 8 wherein said at least one layer is a base coat and said medical device further comprises a top coat applied over said base coat. 10. The medical device according to claim 9, wherein bioactive material-containing spheres are found in a location selected from the group consisting of within said base coat, within said top coat, between said base coat and said top coat and combinations thereof. 11. The medical device according to claim 10 where said bioactive material-containing spheres comprise of a biodegradable polymer. 12. The medical device according to claim 9, wherein said base coat and/or said top coat comprise a sol-gel inorganic oxide composition. 13. The medical device according to claim 8, wherein said base coat comprises a mesoporous oxide with substantially continuous interconnected channels. 14. A medical device comprising a structural element and a bioactive material-eluting coating, wherein said bioactive material-eluting coating comprises at least two layers with at least one of said layers comprising a matrix composition having an inorganic oxide formed using a sol-gel process wherein the inorganic oxide is compounded with an agent that modifies a characteristic of said inorganic oxide selected from the group consisting of hydrophobicity, charge, biocompatibility, mechanical properties, bioactive material affinity, storage capacity, and combinations thereof wherein the environment of said sol-gel process wasis tailored to the characteristics of a bioactive material to be incorporated into said matrix composition said tailoring affecting the amount of said bioactive material within said matrix composition once formed and/or the rate of release of said bioactive material into the physiological environment once implanted in a patient. 15. The medical device according to claim 14 wherein said at least two layers comprise a base coat and a top coat and said base coat is applied to said surface of said medical device and said top coat is applied over said base coat. 16. The medical device according to claim 14, wherein at least one of said at least two layers comprises a form selected from the group consisting of a solgel oxide layer without bioactive material; a sol-gel oxide layer with bioactive material incorporated in the oxide; a sol-gel oxide compounded with an organically modified silane without bioactive material; a sol-gel oxide compounded with an organically modified silane with bioactive material; an organically modified silane layer without bioactive material; an organically modified silane layer with bioactive material; a mesoporous oxide without bioactive material; a mesoporous oxide with bioactive material incorporated in the oxide; a mesoporous oxide with bioactive material incorporated in the oxide and additional bioactive material loaded into its interconnected channels after the mesoporous oxide is applied to said surface of said medical device; a mesoporous oxide with no bioactive material incorporated in the oxide but with bioactive material loaded into its interconnected channels after the oxide is applied to said surface of said medical device; and a collection of bioactive material containing polymer spheres.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.